Close

Cantor Defends Unilife (UNIS) Against Short Seller

April 22, 2014 3:47 PM EDT
Get Alerts UNIS Hot Sheet
Price: $0.16 --0%

Rating Summary:
    4 Buy, 2 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 7 | Down: 3 | New: 1
Join SI Premium – FREE

Cantor Fitzgerald is defending Unilife Corp. (Nasdaq: UNIS) following a negative blog post made Tuesday.

Analyst Jeremy Feffer noted that the article brings nothing new to the table. The analyst commented, At the heart of the author's argument is the existence of "law enforcement investigations," which we believe refers to an ongoing SEC investigation. We note that this investigation is more than a year old and was already public knowledge when Unilife signed long-term supply agreements with Sanofi, Hikma, Astra-Zeneca, and Novartis and when it recently reached a debt financing agreement with OrbiMed. Given that today's article presents no information that has not already been digested by the market, we see no reason why the stock should be down 10% today.

Feffer has Unilife at Buy with a price target of $8.

For an analyst ratings summary and ratings history on Unilife Corporation click here. For more ratings news on Unilife Corporation click here.

Shares of Unilife Corporation closed at $3.58 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Momentum Movers, Short Sales, Trader Talk

Related Entities

Cantor Fitzgerald